Kornimate/medical-research-clean huggingface dataset:
oxytocin, stress, craving, opioid use disorder

Conditions: Opioid Use Disorder

Summary: although stress has long been linked to substance use, craving and relapse, there are no available medications that target stress-induced substance use disorder (sud). in particular, with the rise in opioid use, there is still a crucial need for developing effective pharmacological treatments that target and integrate the complexity of this disease. the long term goal of this project is to identify the key neuroendocrine pathways that are responsible for stress-induced craving in individuals with opioid use disorder (oud) in order to better understand how they can be effectively treated.

the goal of this research is to evaluate whether oxytocin, a hormone with anti-stress properties, dampens the effects of stress and opioid-associated cues on opioid craving and thus may be an effective adjunctive treatment for oud. the central hypothesis of this research is that oxytocin will reduce stress-induced opioid craving in patients with oud treated with buprenorphine/naloxone as opioid replacement therapy (ort). this hypothesis is based on the model of addiction (koob, neuron 2008) in which chronic substance use and stress lead to neurobehavioral counter-adaptations that dysregulate biobehavioral response. in this double-blind, cross-over, placebo controlled, randomized trial, individuals with oud (n=20 who are currently receiving treatment with buprenorphine/naloxone or methadone will be randomized to intranasal oxytocin (40 international units, iu) and oxytocin-matched placebo, administered twice/day for 7 days with a minimum of two days between the opposite condition (oxytocin or placebo). on days 5 and 7, and on days 14 and 16, participants will complete two counter-balanced sessions in which they receive yohimbine (32.4 mg) or yohimbine-matched placebo.

Eligibility criteria:
inclusion criteria: * male or female (50%), 18 to 70 (inclusive) years of age; * currently meets dsm-5 criteria for oud; * currently on a stable dose of buprenorphine/naloxone or methadone for at least 3 months; * in good health as confirmed by medical history, physical examination and blood work (liver function within 5x the upper normal limits (ast/alt) and renal function within 2x the lower normal limit (bilirubin, creatine clearance). * willing to take medication and adhere to the study procedures;- understand informed consent and questionnaires in english at an 8th grade level; * clinical opiate withdrawal scale (cows) = 0 at study screening and prior laboratory sessions. exclusion criteria: * women who are breastfeeding, test positive for pregnancy or are unwilling to use medically-approved birth control; * suicide attempts in the last three months; * current substance disorder other than marijuana, nicotine and caffeine as assessed by self-report and urine toxicology screen at baseline; * current use of medications that may interact with study medications; * history of hypersensitivity to study medications; * clinically significant electrolyte abnormalities, current rhinitis or use of vasoconstricting medications or prostaglandins.
home-based respiratory training on swallowing in stroke

Conditions: Stroke

Summary: the aim of this study is to evaluate the effects of a home-based respiratory muscle training on swallowing function in patients with chronic stroke. the patients will be included in a experimental or a control group. the patients in the experimental group will receive a home-based respiratory training using respiratory devices added to standard treatment, while the participants in the control group will only receive the standard treatment.

this study aims to evaluate the effects of a home-based respiratory muscle training on swallowing function in patients with chronic stroke. the patients will be included in a experimental or a control group. the patients in the experimental group will receive home-based respiratory training using respiratory devices added to standard treatment, while the participants in the control group will only receive the standard treatment. the swallowing function will be assessed using specific tools and questionnaires. secondary outcomes will evaluate the respiratory function. the intervention will have a duration of 6 weeks.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of stroke * 18 years of age or more exclusion criteria: * cognitive impairment or aphasia that prevents the understanding of instructions. * tracheostomy. * presence of cancer. * patients who present another disease of the central nervous system * absence of neuromotor competence to carry out the respiratory function tests. * central apnea. * hypoventilation-obesity syndrome. * severe cardiorespiratory impairment (hemodynamic instability, pulmonary embolism, recent pneumonothorax, acute hemoptysis, active respiratory infections, recent myocardial infarction, unstable angina, pulmonary hypertension, uncontrolled asthma, or severe chronic obstructive pulmonary disease). * patients with recent otorhinolaryngological, abdominal, or thoracic surgery.
orientation for hearing aid users: information retention

Conditions: Hearing Loss

Summary: aim: to verify how much of the orientation provided at diagnosis and hearing aid fitting are retained by new hearing aid users and analyze whether age, degree of hearing loss, academic and socio-economics status have an influence on this

introduction: the understanding and retention of orientations provided by the health professional increases patient's satisfaction and compliance to treatment and reduces treatment duration and costs. aim: to verify how much of the orientation provided at diagnosis and hearing aid fitting are retained by new hearing aid users and analyze whether age, degree of hearing loss, academic and socio-economics status have an influence on this. methods: participated in this study 30 adults (18 female and 12 male) with age varying from 18 to 88 years, with post lingual uni or bilateral hearing loss of various degrees and types. orientations were offered at the time of diagnosis and hearing aid fitting. at the first follow up visit patients were interviewed regarding their hearing loss' characteristics as well as hearing aid care and use (probed recall task). it was also evaluated how participants manipulated their devices. a protocol was used to score participant's responses. results: on average participants could retain 31,6% and 83,6% of the orientation provided regarding their hearing loss and hearing aid care and use. there was a negative correlation between age and amount of information retained. there was no influence of degree of hearing loss, academic and socio-economic statues. conclusion: the hearing impaired patients have difficulty to recall orientation provided therefore the use of facilitation strategies to information retained is necessary.

Eligibility criteria:
inclusion criteria: * older than 18 years old * sensorineural hearing loss, hearing aid candidate exclusion criteria: * severe dexterity or visual problems. cognitive or memory disorders

Keywords: hearing aids counseling
neuromuscular electrical stimulation and physical function in older adults

Conditions: Sarcopenia

Summary: the purpose of this placebo controlled clinical trial is to examine the effects of of neuromuscular electrical stimulation (nmes) training on physical activity, muscle function, self-efficacy, and blood markers \[e.g., brain-derived neurotrophic factor (bdnf)\] in older adults. it is hypothesized that 4-weeks of nmes will increase 1) physical activity, 2) muscle function, 3) self-efficacy, and 4) bdnf in older adults. sarcopenia is a destructive progressive cycle of impaired physical function resulting in loss of muscle mass, strength, and self-confidence in ability to perform physical activities, compounded by difficulty walking and ultimately reduced physical activity levels for many older adults. neuromuscular electrical stimulation (nmes) is a common therapeutic modality used to create involuntary muscle contractions as a means to increase muscle strength, and may be an effective treatment for improving muscle function and physical activity levels in older adults with sarcopenia. thus, it is critical to explore viable and effective alternative therapies to increase physical activity. the goal of the investigators' is to determine the effectiveness of neuromuscular electrical stimulation (nmes) at increasing physical activity and related biological, psychological, and muscle function factors. this placebo controlled clinical trial will use a pre-test - post-test randomized experimental design.

older healthy adults (60 and older) will participate in this study. participants will undergo 4 weeks of neuromuscular electrical stimulation (nmes) training. participants will be randomized into the one of two groups 1) nmes-millicurrent or 2) nmes microcurrent. participants will undergo pre- and post-training testing for muscle function, physical function, and psychological variables related to physical activity. blood samples will also be obtained pre- and post-training.

Eligibility criteria:
inclusion criteria: * generally healthy men and women * ages 60 and older exclusion criteria: * 1) they have participated in regular resistance training exercise or physical rehabilitation of the lower extremity within 2 months of the study * 2) contraindicating conditions for electrical stimulation are present (i.e., swollen, infected or inflamed areas including open wounds, or painful areas on the lower limbs, implanted electronics including cardiac pacemakers, electronic infusion pumps, implanted stimulators, or surgical hardware in the lower limbs) * 3) they have current knee injury or knee pain * 4) have a neuromuscular disease * 5) currently taking insulin for diabetes regulation * 6) they have a history of seizures

Keywords: neuromuscular electrical stimulation physical activity muscular strength
the short-term efficacy of novel ntdp-rfa in the treatment of small hcc with cirrhosis.

Conditions: Hepatocellular Carcinoma Stage I; Radiofrequency Ablation

Summary: to evaluate the short-term efficacy of novel no-touch combined directional perfusion radiofrequency ablation in the treatment of small hepatocellular carcinoma with cirrhosis.

liver cancer is the fourth leading cause of cancer-related deaths globally. hepatocellular carcinoma (hcc) accounts for 70% to 85% of primary hcc and is the leading cause of death in patients with cirrhosis. we developed a novel no-touch combined directional perfusion radiofrequency ablation system.by inserting two or more electrodes around the tumor and activating them simultaneously.the hypertonic saline solution can be directed into the focal tissue from a lateral pore through a tube within the electrode to provide more uniform and thorough necrosis.the maximum ablation volume was increased while the loss of normal tissue in the non-injection direction was reduced, thus reducing the incidence of postoperative complications. therefore, the purpose of this study was to evaluate the short-term efficacy of novel no-touch combined directional perfusion radiofrequency ablation in the treatment of small hepatocellular carcinoma with cirrhosis.

Eligibility criteria:
inclusion criteria: * primary hepatocellular carcinoma with a background of cirrhosis * single shot with diameter ≤ 3cm * the tumor did not invade portal vein, hepatic vein trunk and secondary branches * child pugh a/b * icg-r15 ≤ 30% * 18-70 years old * the follow-up time reached 2 years exclusion criteria: * the follow-up time is less than 2 years * multiple lesions or diameter \> 3cm * previous history of upper gastrointestinal bleeding or severe hypersplenism * patients with extrahepatic or lymph node metastasis * wish to receive liver transplantation and hepatectomy * the lesion is adjacent to the gallbladder, important blood vessels and bile ducts in the hilum of the liver and important organs around * severe bleeding tendency, platelet count \ 3s * other anti-tumor therapies were accepted before surgery
effekt-2 - efficacy and safety of long-term treatment with kogenate® fs in latin america

Conditions: Blood Coagulation Disorders; Hemophilia A

Summary: the aim of this international prospective post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of kogenate bayer/fs in treatment of patients with haemophilia a under daily-life treatment conditions.


Eligibility criteria:
inclusion criteria: * patients with diagnosis of hemophilia a, independent of age, treated with kogenate® fs as their only source of fviii, decision taken by the investigator to administer kogenate® fs. for pretreated patients with more than 100 exposure days an inhibitor assessment within three months prior to enrollment should be available; for pretreated patients with less than 100 exposure days an inhibitor assessment at baseline should be available.

Keywords: octocog alfa hemophilia a
a clinical study of mk-1084 in participants with renal impairment (mk-1084-010)

Conditions: Healthy; Renal Impairment

Summary: the goal of this study is to learn what happens to mk-1084 levels in a person's body over time. researchers will measure what happens to mk-1084 levels in the body when it is given to people with moderate or severe renal impairment (ri) (meaning the kidneys do not work properly) as compared to people who are in good health. researchers also want to learn about the safety of mk-1084 when it is given to people with ri and if people with ri can tolerate it.


Eligibility criteria:
inclusion criteria: the main inclusion criteria include but are not limited to the following: all participants: - has a bmi ≥18.0 and ≤40.0 kg/m\^2 participants with severe or moderate ri: * with the exception of ri, is sufficiently healthy for study participation * has stable renal function with no clinically significant change in renal status at least 29 days prior to dosing and is not currently or has not been previously on dialysis for at least 1 year participants with normal renal function: - is medically healthy exclusion criteria: the main exclusion criteria include but are not limited to the following: all participants: * has a history of cancer (malignancy) * has positive results for human immunodeficiency virus, hepatitis b surface antigen, or hepatitis c virus * has had major surgery and/or donated or lost significant volume of blood within 56 days prior to dosing participants with severe or moderate ri: * has a history or presence of renal artery stenosis * has a renal transplant or nephrectomy
safety and efficiency study of bcma-pd1-cart cells in relapsed/refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: this is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of bcma-pd1-cart cells therapy for patients with relapsed/refractory multiple myeloma.

previous studies have found that multiple myeloma cells express pd-l1 at a high level. therefore, the combination of anti-pd-1 or pd-l1 antibodies with cart therapy may further improve the clinical efficacy of cart cell for multiple myeloma. the investigators screened pd-1 mutant that have high affinity bind with the pd-l1 ligand, and the affinity of the prepared mutant pd-1 fc fusion protein to bind to pd-l1 reached clinical anti-pd-l1 antibody levels. the investigators prepared bcma cart cells which secretes the mutant pd-1fc fusion protein, and the prepared cart cell culture supernatant can well block the binding of pd-l1 to pd-1. preclinical studies have shown that bcma cart cells secreting mutant pd-1fc fusion protein have a superior killing effect on pd-l1 positive multiple myeloma tumor cells to bcma cart cells which does not express pd-1 fusion protein. the trial was conducted to explore the safety and efficacy of bcma-pd1-cart cells in relapsed/refractory multiple myeloma.

Eligibility criteria:
inclusion criteria: 1. male or female, aged 14 to 80 years (including 14 and 80 years old). 2. the diagnosis was refractory/relapsed multiple myeloma.(meeting 1 of the follow 3 items) a.primary treatment patients with no effect after first and second line treatment. b.patients who relapsed after complete remission and failed to respond to two kind of therapy. c.the predicted survival is more than three months. 3. flow cytometry or immunohistochemistry showed bcma positive in tumor cells. 4. patient or his or her legal guardian voluntarily participates in and signs an informed consent form. 5. no serious concomitant disease and major organ function is not serious abnormal. 6. no serious concomitant disease and major organ function is not serious abnormal. 7. the test meets the following indicators: a.alt/ast \< 2.5 times the upper limit of normal (uln) and total bilirubin≤34.2μmol/l. b.wbc≥2.5×109/l. c.pt/inr \< 1.7 or pt was extended by less than 4 seconds. exclusion criteria: 1. women who are pregnant or breastfeeding. 2. transduced positive t lymphocytes \< 5% or amplified against cd3/cd28 stimulation \< 5 times. 3. active hepatitis b or hepatitis c, hiv/aids infection, any uncontrolled active infection. 4. patients who are using steroid drugs throughout the body currently. 5. patients who have received any gene therapy in the past. 6. patients who are allergy to immunotherapy and related drugs. 7. patients with heavy heart disease or poorly controlled high blood pressure. 8. patients who received chemotherapy or radiation 4 weeks before the study began. 9. patients who are participating in other clinical trials.

Keywords: bcma myeloma pd-1 immunotherapy plasmocytoma chimeric antigen receptor t cell chimeric antigen receptor b cell maturation antigen
the effect of branched-chain amino acid (bcaa) on the progression of primary liver cancer

Conditions: Primary Liver Cancer

Summary: supplementation of bcaa found to reduce the risk of developing liver cancer, but the affect of bcaa on existing liver cancer is unknown. the participants (post curative intent surgery) will be supplemented with either bcaa/non-bcaa-enriched protein supplement. the intervantion will go on for 2 years or until a new liver tumor is found.


Eligibility criteria:
inclusion criteria: * diagnosed primary liver cancer * viral or nonalcoholic steatohepatitis cirrhosis * cirrhosis rated child-pugh a * liver cancer rated barcelona clinic liver cancer (bclc) a exclusion criteria: * age (over 65) * liver condition rated child-pugh b/c * gi/absorption issues * patients given a treatment before surgery
norwegian sars-cov-2 study - virological, clinical and immunological characterisation of covid-19

Conditions: SARS Virus; Severe Acute Respiratory Syndrome

Summary: oslo university hospital has initiated an observational study on hospitalised patients with confirmed covid-19, the infection caused by severe acute respiratory syndrome coronavirus type 2 (sars-cov-2).

infectious disease is the single biggest cause of death worldwide. new infectious agents, such as the sars-cov-2, require investigation to understand pathogen biology and pathogenesis in the host. in order to develop a mechanistic understanding of disease processes, such that risk factors for severe illness can be identified and treatments can be developed, it is necessary to understand pathogen characteristics associated with virulence, the replication dynamics and in-host evolution of the pathogen, the dynamics of the host response, the pharmacology of antimicrobial or host directed therapies, the transmission dynamics, and factors underlying individual susceptibility. at oslo university hospital, an observational study on the newly discovered emerging sars- cov-2, the coronavirus that causes covid-19 infection has started. the study has been approved by the regional ethics committee, so that inclusion of confirmed covid-19 cases admitted at the hospital can start immediately including the first patients needing hospitalisation. the plan is to include more hospitals in other parts of norway, starting with inclusion of akershus university hospital, vestre viken drammen hospital and østfold hospital. the study is anticipated to provide much needed data on the course of the covid-19 infection, as well as generating knowledge about the virus and its transmission.

Eligibility criteria:
inclusion criteria: * confirmed covid-19 by screening of sars-cov-2 e-gene exclusion criteria: * refusal of consent by patient or closest relative
comparing preschool-aged refractive measurements and amblyopia risks using the 2win-s portable refractor with vision screening by cycloplegic refraction in bangkok

Conditions: 2WIN-S Portable Refractor

Summary: the goal of this diagnostic test is to compare the results of refraction and amblyopia risks between using 2win-s portable refractor and cycloplegic refraction in pre-school age. all participants will be tested by 2win-s portable refractor.


Eligibility criteria:
inclusion criteria: * corrected visual acuity 0.1 logmar (snellen 20/25) or better * age 3-6 years old who studies in the kindergarten school that joins the study * parents sign informed consent form about allowing their child to join the study exclusion criteria: * other eye conditions causing visual and 2win-s portable refractor working disturbance such as media opacity, history of ocular surgery, strabismus, etc.

Keywords: refraction vision screening preschool aged children
intravaginal laser treatment of mild and moderate stress incontinence

Conditions: Stress Incontinence, Female

Summary: the aim of the study is to evaluate the effectiveness of laser therapy as a non-surgical treatment option in patients with mild and moderate stress incontinence.

the aim of the study is to evaluate the effectiveness of laser therapy as a non-surgical treatment option in patients with mild and moderate stress incontinence.

Eligibility criteria:
inclusion criteria: * light or moderate stress incontinence * mixed urine incontinence with predominance of the stress component * written informed consent exclusion criteria: * pregnancy * patients treated radiotherapy in the small basin * connective tissue disorders (e.g., ehlers-danlos syndrome, marfan syndrome) * patient with or after malignant disease of the uterus, ovaries, vagina and vulva * former surgery due to stress incontinence (except for the patients who had a tvt insert with removal of the tvt) * descensus genitalis\> popq stage 1 * former surgery due to a genital lowering with vaginal netting